Temad Company
Temad Co. (Tolid Mavade Avallieh Daroupakhsh) is a Tehran-listed Iranian manufacturer of active pharmaceutical ingredients and semi-finished pharmaceutical materials. Owned by TPICO within the SHASTA group, it operates production sites in Alborz and Mashhad and serves domestic pharmaceutical manufacturers alongside export markets in 56 countries. Its controlled-substance API capability and upstream role make it a significant pharmaceutical-supply-chain company.
Market position
Temad describes itself as the leading exporter of pharmaceutical APIs among listed companies for several consecutive years. It also positions itself as a major regional producer of narcotic and non-narcotic APIs.
Operations & footprint
Products and services
Temad Company manufactures active pharmaceutical ingredients, narcotic and non-narcotic APIs, semi-finished pharmaceutical materials, pellets, direct-compression grades, finished dosage forms, synthetic narcotics, controlled pharmaceutical raw materials, veterinary APIs, and knowledge-based pharmaceutical products. It operates as an API producer within the TPICO and SHASTA-linked pharmaceutical ecosystem.
Operations and assets
The company operates two production sites and 20 production lines. The Alborz site produces high-technology, low- and high-volume, and narcotic products; the Mashhad site focuses on high-volume products. Temad also holds an accredited reference-laboratory licence.
Geographic footprint
Headquartered in Alborz, with manufacturing sites in Alborz and Mashhad, Razavi Khorasan. Temad exports to 56 countries across five continents.
Ownership & group structure
Ownership
A public joint-stock company listed on the Tehran Stock Exchange since 24 November 2002 under ticker دتماد.
Parent company
Tamin Pharmaceutical Investment Company (TPICO), within the Social Security Organization (SHASTA) group.
Reported scale
Employees: More than 600 employees.
Commercial and investment relevance
Temad is relevant for investors assessing Iran's API localization, listed pharmaceutical exposure, controlled-substance manufacturing, export-oriented pharmaceutical raw materials, and dependence of downstream drug producers on domestic inputs. It can support analysis of medicine-supply resilience, margin sensitivity to regulated pricing, export sales, raw-material import exposure, and technology capability in complex chemical synthesis. Due diligence should review updated Codal disclosures, ordinary-share trading status, product registrations, narcotic and non-narcotic API licenses, GMP certifications, export markets, TPICO ownership, regulatory controls, environmental compliance, supplier dependencies, and sanctions or controlled-substance compliance risk. Temad is an upstream supplier to pharmaceutical manufacturers requiring APIs, pellets and direct-compression materials. Its controlled and non-controlled API range, two-site production platform and international export activity are particularly relevant for buyers seeking Iranian pharmaceutical-input supply.
Constraints, risk & compliance
Key risks and constraints
Manufacturing narcotic APIs and addiction-treatment replacement drugs requires stringent product controls, licensing and quality compliance. The company’s export-facing model also depends on maintaining product registrations, quality-system acceptance and reliable cross-border delivery for regulated pharmaceutical materials.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around Temad Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does Temad Co. manufacture?
Temad manufactures active pharmaceutical ingredients and semi-finished pharmaceutical materials, including pellets and direct-compression grades, alongside selected finished dosage forms.
Where are Temad’s production sites?
Temad operates two production sites: one in Alborz Province and another in Mashhad, Razavi Khorasan Province.
Is Temad listed on the Tehran Stock Exchange?
Yes. Temad has been listed on the Tehran Stock Exchange since 24 November 2002 under ticker دتماد.
Who owns Temad?
Temad is owned by Tamin Pharmaceutical Investment Company (TPICO), which sits within the Social Security Organization (SHASTA) group.